Adjuvant hormone therapy in locally advanced and localized prostate cancer: three EORTC trials.
Bolla
M
M
EORTC Radiotherapy and Genito-Urinary Cooperative Groups, EORTC Data Center, Brussels, Belgium. MBolla@chu-grenoble.fr
de Reijke
Th M
TM
Zurlo
A
A
Collette
L
L
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005221:Fatigue / Q000139:chemically induced; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D017273:Goserelin / Q000009:adverse effects / Q000627:therapeutic use*; D019584:Hot Flashes / Q000139:chemically induced; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D011788:Quality of Life; D020266:Radiotherapy, Conformal; D016032:Randomized Controlled Trials as Topic; D012735:Sexual Dysfunction, Physiological / Q000139:chemically induced; D015996:Survival Rate; D013739:Testosterone; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone